Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and chemotherapy in unresectable NSCLC
NCT04144608Phase 2Completed
- Sponsor
- Yongchang Zhang
- Start
- Jan 2020
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by Yongchang Zhang. Started Jan 2020; status: completed.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04144608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04144608.